Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Didymin: an orally active citrus flavonoid for targeting neuroblastoma

8 Feb 2017

Abstract excerpt

// Sharad S. Singhal 1 , Sulabh Singhal 2 , Preeti Singhal 3 , Jyotsana Singhal 1 , David Horne 1 and Sanjay Awasthi 4 1 Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA 2 University of California at San Diego, La Jolla, San Diego, CA, USA 3 University of Texas Health, San Antonio, TX, USA 4 Texas Tech...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28187004
DOI: 10.18632/oncotarget.15204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Didymin: an orally active citrus flavonoid for targeting neuroblastomaPMID 28187004Read ↗

Neuroblastoma: An Updated Review on Biology and TreatmentSemantic proximity Read ↗

RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Semantic proximity Read ↗

Neuroblastoma: A Tough Nut to Crack.Semantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

Neuroblastoma and its Target Therapies: A Medicinal Chemistry ReviewSemantic proximity Read ↗

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventionsSemantic proximity Read ↗

Investigational drugs in phase II clinical trials for the treatment of neuroblastomaSemantic proximity Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

New Insights into Neuroblastoma Cisplatin Resistance: A Comparative Proteomic and Meta-Mining InvestigationSemantic proximity Read ↗

DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastomaSemantic proximity Read ↗

Neuroblastoma therapy: what is in the pipeline?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.